跳至主要内容
临床试验/NCT01226602
NCT01226602已完成1 期

A Randomized, Double-blind, Placebo Controlled, Crossover, Single Centre Phase I Study to Assess the Effect of Ticagrelor on Adenosine-induced Coronary Blood Flow Velocity in Healthy Male Subjects

AstraZeneca1 个研究点 分布在 1 个国家目标入组 39 人开始时间: 2010年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
AstraZeneca
入组人数
39
试验地点
1
主要终点
Assess the effect of Ticagrelor compared to placebo on the adenosine induced coronary blood flow velocity response by estimating the change in area under the adenosine dose response curve before and after study drug.

研究概览

简要总结

The purpose of this study is to determine if Ticagrelor increases the Adenosin induced coronary blood flow velocity.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Suitable for ECG recording of CBFV and have no adverse reaction to adenosine challenge
  • Have a body mass index between 18 and 30 kg/m2

排除标准

  • History of clinically significant disease or disorder.
  • Abnormal vital signs

研究组 & 干预措施

1

Experimental

Adenosinladder; Ticagrelor (180 mg), Adenosinladder ; Theophylline (5 mg/kg), Adenosinladder

干预措施: AZD6140 (Drug)

2

Placebo Comparator

Adenosinladder; Placebo, Adenosinladder; Theophylline (5 mg/kg), Adenosinladder

干预措施: Placebo (Drug)

结局指标

主要结局

Assess the effect of Ticagrelor compared to placebo on the adenosine induced coronary blood flow velocity response by estimating the change in area under the adenosine dose response curve before and after study drug.

时间窗: During 6 h at visit 3

次要结局

  • Effect of Ticagrelor compared to placebo on the adenosine induced coronary blood flow velocity by estimating the change in area under the adenosine dose response curve before and after infusion of theophylline.(During 6 h at visit 2)
  • Difference in basal blood flow (in the absence of adenosine) between Ticagrelor and placebo conditions before and after infusion of theophylline.(During 6 h at visit 3)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Study to Assess the Effect of Ticagrelor on Coronary... | 临床试验